Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics
For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh
Read more
Revive Therapeutics
Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research
Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms.
Read more
Revive Therapeutics Completes Psilocybin Oral Thin Film Strip Product
Revive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The
Read more
Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19
Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three clinical trials for the evaluation
Read more
Havn Life to Supply Revive Therapeutics With Psychedelic Compounds
This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn Life Sciences Inc. (CSE : HAVN) to source
Read more
Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials
This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical sites in Florida, Texas and
Read more
Revive Sees Expanded Access Protocol Approved For Compassionate Use Of Bucillamine
Revive Therapeutics (CSE: RVV) this morning announced that it has received approval from the Independent Institutional Review Board (IRB) for
Read more
Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin
Revive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this morning that it has entered
Read more
Revive Receives Approval From Independent Review Board For Phase Three Study
Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials for the use of Bucillamine
Read more
Revive Submits for IRB Approval; Expects to Enroll Patients in September
This morning Revive Therapeutics (CSE: RVV, USA: RVVTF) announced they have submitted a clinical trial protocol to their independent Institutional
Read more